THE MODEL OF PSYCHOPATHOGENESIS OF NONPSYCHOTIC MENTAL DISORDERS IN PERSONS UNDERGOING THE PROGRAMS OF SYNTHETIC OPIOIDS SUBSTITUTION THERAPY.
Abstract
In order to identify the structural and dynamic characteristics of comorbid non-psychotic psychopathological symptoms in patients on the synthetic opioid substitution therapy program, 100 patients of the narcological dispensary were examined with the help of the Simptom Check List – 90 – Revised. The study used the inclusion and exclusion criteria that are identical to the criteria for participation in the substitution therapy program. The results were distributed to 3 levels, which correspond to the degree of clinical significance of the symptoms: - minimal (discomfort for this reason occurs rarely or does not occur at all, it has a low intensity) - the range of results obtained is from 0 to 0.50; - subclinical (the presence of not frequent, moderately intense discomfort for this reason) - the range of values is from 0.51 to 1.50; - clinical (frequent or persistent high intensity discomfort for this reason) - range of values greater than 1.51. The study found that non-psychotic mental disorders among this group of patients have three stages of development. All groups of symptoms are considered in the context of the three main classes of disorders (patho-affective — anxiety and depression symptoms; pseudo-neurotic — obsessive-compulsive phenomena; psycho-vegetative symptoms and self-perception disorders; and psychoorganic — associative disorders, paranoia and hostility) and two groups of intermediate symptoms (phobic — intermediate between pathogenic and pseudoneurotic and psychotic - intermediate between psychoorganic and pseudoneurotic). Also, according to the results of the assessment of the correlation dynamics of symptom groups, a model of psycho-pathogenesis of non-psychotic mental disorders in people who are on the program of drug addiction substitution therapy was constructed
Downloads
References
Trujols J. Patient perception of methadone dose adequacy in methadone maintenance treatment: The role of perceived participation in dosage decisions / J. Trujols, F. González-Saiz, M. J. Manresa // Patient Education and Counseling. – 2017. – Vol. 100, № 5. – P. 981–986.
Барановский Н. А. Социальная профилактика наркомании среди молодежи / Н. А. Барановский // Социологический альманах. – 2017. – № 8. – С. 115–126.
Pharmacogenomics of methadone maintenance treatment / A. A. Somogyi, D. T. Barratt, R. L. Ali, J. K. Coller // Pharmacogenomics. – 2014. – Vol. 15, № 7. – P. 1007–1027.
Цыганков Б. Д. Подходы к лечению абстинентного, постабстинентного состояния наркологических больных / Б. Д. Цыганков, С. А. Шамов, М. Н. Земсков // Росс. мед. журн. – 2013. – № 4. – С. 32–36.
Wang G. Y. Methadone maintenance treatment and cognitive function: a systematic review / G. Y. Wang, T. A. Wouldes, B. R. Russell // Current Drug Abuse Reviews.
– 2013. – Vol. 6, № 3. – P. 220–230.
Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran / M. Farnia, B. Ebrahimi, A. Shams, S. Zamani // International J. of Drug Policy. – 2010. – Vol. 21, № 5. – P. 422–424.
Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians / P. Roux, C. Lions, L. Michel [et al.] // Current Pharmaceutical Design. – 2014. – Vol. 20, № 25. – P. 4097–4105.
Incarcerated intravenous heroin users: predictors of post-release utilization of methadone maintenance treatment / H. C. Lin, P. W. Wang, Y. H. Yang [et al.] // J. of Addictive Diseases. – 2016. – Vol.
, № 2. – P. 109–118.
Гребенюк А. А. Клинико-психологический анализ непсихотических психических расстройств у бывших участников программы заместительной поддерживающей терапии и их влияние на мотивацию к прохождению медицинской реабилитации / А. А. Гребенюк // Наркология. – 2016. – № 6. – С. 72.
